EyeProGPO Signs Vendor Agreement with Bio-Tissue, Inc. to Afford Members New Ocular Surface Disease and Disorder Treatment Options that Promote Regenerative Healing
Athens, Georgia Oct 5, 2021 (Issuewire.com) - EyeProGPO, LLC ("EyePro"), a group purchasing organization ("GPO") that assists healthcare providers and ambulatory surgery centers ("ASCs") achieve cost savings and related efficiencies through membership purchasing volume discount programs with vendors, has entered into a Vendor Agreement with Bio-Tissue, Inc. Bio-Tissue is a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders.
EyePro GPO members can now access Bio-Tissue's portfolio of tissue-engineered solutions to treat ocular surface disease, injuries, and disorders, as well as ocular hygiene solutions for eye care professionals. This agreement represents one of many agreements between EyePro and its contracted suppliers of products for use within its GPO member surgery centers and medical practices.
Phil Meyer, Chief Operating Officer of EyePro, said, "With reimbursements for services declining, ASCs and office-based physicians must evaluate all expenditures, especially supply and implant costs, to continue to provide services. We are excited to have Bio-Tissue as a partner in providing human birth tissue and other ophthalmology products with projected lower healthcare costs."
Thomas Williamson, TissueTech Chief Commercial Officer, further reiterated the benefits of the agreement that will assist EyePro members in purchasing cryopreserved human birth tissue products to treat patients in both the surgical and practice-based setting. "The agreement between Bio-Tissue and EyePro affords GPO members significant opportunities to address unmet patient needs and expeditiously facilitate optimal clinical outcomes. We are delighted to have been awarded a contract with this esteemed GPO and applaud their innovation and commitment to the delivery of high quality, cost-effective patient care."
EyeProGPO looks forward to a long, collaborative relationship with Bio-Tissue. It continues to develop its group purchasing organization across the United States and establish itself as the leading group purchasing organization for the ophthalmology community. This agreement will assist EyePro members in purchasing cryopreserved human birth tissue products to treat patients in both surgical and practice-based settings. Additionally, as part of its expanding contract portfolio offering, it is projected that this agreement will reduce associated healthcare delivery costs.
About EyeProGPO, LLC
EyeProGPO is an ophthalmology-focused group purchasing organization made up of members who are either or both ophthalmology practices and/or ophthalmic ASC's, joining together to realize cost savings and workflow efficiencies by utilizing aggregated membership purchasing volume to negotiate discounts with manufacturers, distributors, and vendors to lower the cost of healthcare. EyeProGPO also collects data and assists vendors in their sales analyses to allow greater efficiency, thereby also reducing costs.
About Bio-Tissue, Inc.
Bio-Tissue, Inc. is a TissueTech, Inc. company. It is pioneering the clinical application of human birth tissue to promote regenerative healing for ocular surface disease and disorders. The Bio-Tissue portfolio of cryopreserved amniotic membrane products is processed using its proprietary CRYOTEK® technology to retain the birth tissue's structural and functional integrity. As a leader in clinical research, Bio-Tissue has been facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients' lives since 1997. Connect with Bio-Tissue on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.
Media Contact
Phil Meyer
18334393776
1150 Julian Drive, Watkinsville GA 30677
Source :EyeProGPO, LLC
This article was originally published by IssueWire. Read the original article here.
